| AGREEMENT |
Avecia Wins US $71 million Anthrax Vaccines Contract Avecia, a leader in biotechnology-derived medicines and vaccines, has been awarded a US $71.3 million contract to make 3 million doses of a new type of recombinant anthrax vaccine for the US Government's National Institute of Allergy and Infectious Diseases (NIAID). Scheduled for completion by late 2006, the contract will continue anthrax vaccine development efforts for NIAID that were initiated with a contract awarded in 2002 to produce 2,000 doses of the new vaccine for clinical trials. This award is consistent with Avecia's ongoing and successful performance associated with the initial contract. The new vaccine is intended to provide immunity to inhalation anthrax in three or fewer doses and to protect individuals from anthrax spores, even if the vaccine is given shortly after exposure. It is planned to replace a current vaccine that requires six injections over 18 months. Production of the new vaccine is based on technology developed by the UK's Defence Science and Technology Laboratory (Dstl), in close co-operation with Avecia, which jointly conceived and engineered the process development and scale-up technologies for large scale, cost-effective GMP manufacture. In preparing the bid, Avecia has also teamed up with Baxter Healthcare Corporation, already a vaccine supplier to the US government, who will provide regulatory expertise, commercial services and support, as well as fill and finishing and final packaging of this vaccine. Avecia CEO Jeremy Scudamore commented, "This contract is a notable success for our Biotechnology business and the strong specialised collaboration we have established with Dstl and Baxter." The active part of the newly developed vaccine - which will be used to provide immunity to inhaled anthrax spores - is based on the microbially derived, purified protein rPA (recombinant Protective Antigen). The vaccine uses similar technology to that used for many modern medicines. It is not based on the anthrax organism itself, or any derivative, and vaccine production poses no risk of exposure to the disease itself. Production of the vaccine for NIAID will comply fully with the US Food and Drug Administration (FDA) requirements, the European Medicines Evaluation Agency (EMEA) and the Medicines and Healthcare products Regulatory Agency (MHRA), which regulates the UK's development, manufacture and sale of all medicinal products. |
| UPDATE | 09.03 |
| COMPANY | Avecia - USA |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |